Through our efforts aimed at social implementation of advanced medicine, such as support of life science research and development of gene therapy, we are working to create a society in which people can stay well and enjoy life.

Support for the development of global life science research

Takara Bio Group offers a wide variety of products and services in the life sciences field, ranging from those for basic research to those with industrial applications. We are supporting the growth of research in the life sciences by providing universities and businesses around the world with a stable supply of these products.



We are developing PCR reagents and other products

that can be useful even outside the laboratory

Tsuyoshi Miyamura

Senior Managing Director


 Takara Bio has developed research reagents for analyzing genes and cells, which we supply to researchers in the life sciences field all over the world. Many of these technologies are useful in other industrial fields, as well as research fields. The PCR technique, which is one such useful technology, is beneficial in various fields, such as infectious diseases, food, and environmental health. Until now, we have been developing products on the assumption that technicians and researchers with specialist skills would be handling the equipment and reagents in a laboratory setting. Our current aim, however, is to develop products that are faster, simpler, and better suited to the needs of actual medical and testing settings outside labs.

Application of genetic analysis technology to testing and diagnostics

As demand for PCR testing grows amidst the pandemic, we are working to build up the testing system by strengthening our production system and providing a stable supply of PCR-related products  and internationally.

We have also actively expanded our genetic analysis technology to testing and diagnostics, and are helping people be well by expanding the scope of this technology.

Initiatives for achieving gene therapies

We have also been working to improve access to medical care for rare diseases by leveraging the biotechnology we have cultivated over many years in clinical development of gene therapy for rare cancers and other rare diseases. We are aiming to bring socially impactful regenerative medicine products such as gene therapies to market through our CDMO business to address unmet medical needs.



We provide a one-stop operation from the manufacture of

various modalities for cell and gene therapies to quality testing

Junichi Mineno

Director & Vice President


 Our Centers for Gene and Cell Processing are the hub for our CDMO business, and the Center for Gene and Cell Processing I started operation in 2014 as a facility for contract development and manufacturing of cell and gene therapies for pharmaceutical companies. To meet growing demand since then, the Center for Gene and Cell Processing II started partial operations in 2020. The expansion of this second center will be completed in fiscal 2024 with the addition of a large 3,000 liter-class bioreactor for virus vector manufacturing and a cell processing room with a proprietary isolator for cell preparations. Along with the expansion, preparations such as training of specialist personnel are well underway. At Takara Bio, we will work on establishing a one-stop system, from manufacturing various modalities to quality testing in both their tangible and intangible aspects.

Takara Bio Group Sustainability Plan 2026

Theme: Supporting life science research and its development around the world

Measures Targets for FY2026 Description
Wide-ranging support for life science research and industrial development. Promote the development of global, multipolar manufacturing facilities (Japan, the U.S., Europe, and China) and support the development of life science research through stable product supply. Move forward with the transfer of manufacturing from China's core plants to Japan, the U.S., Europe, and India.
Contributing to life science community. (1) Disseminate information about biotechnology fundamentals and the latest technology by holding seminars and workshops. ・Hold about 250 webinars a year for bio-researchers.
・Hold corporate sponsored seminars at academic societies (several times a year).
(2) Commercialize promising academic discoveries through open innovation. As a commercialization of academic technology seeds, started clinical trials of JAK/STAT techniques (TBI-2001), etc.
(3) Promote social understanding of biotechnology. ・Participation in seminars held by universities and scientific organizations (several times a year).
・Holding public relations workshops for university students (once or twice a year).

Theme: Application of gene analysis technologies to testing and diagnosis


Targets for FY2026


Supply testing and diagnostic kits for viruses, etc.

Expand the scope of application by developing "glocal" products customized to the characteristics and demands of each region in the world, in addition to virus testing products for infectious diseases that are prevalent worldwide.

Expand the range of viruses and microbial species to be tested in line with the “glocal” needs.

Theme: Initiatives to develop gene therapy

Measures Targets for FY2026 Description
Promote the development of gene therapy-related technologies that meet unmet medical needs. (1) Proceed with preparation for marketing authorization for TBI-1301 and make it a social implementation. Promote preparations for marketing authorization for TBI-1301.
(2) Promote CDMO business to support the development/ manufacturing of regenerative medicine/ gene and cell therapy. Provision of services for diverse modalities and mass production.
(3) Provide ancillary materials compatible with new modalities. Developing and launching enzymes for the production of mRNA.